Regeneron beats estimates by maintaining Eylea sales and driving Dupixent growth

6 August 2019

One of big pharma’s favorite partner companies – Regeneron Pharmaceuticals (Nasdaq: REGN) – has beaten analyst expectations with its second quarter 2019 financial results.

The US biotech clocked total revenue of $1.93 billion, up 20% on the $1.61 billion of the second quarter of 2018, and ahead of the average analyst estimate of $1.8 billion, according to IBES data from Refinitiv.

"We are further unlocking Eylea’s potential to help patients with the recent approval in diabetic retinopathy, and are advancing a high-dose formulation into the clinic later this year"Regeneron’s investment in Alnylam Pharmaceutical (Nasdaq: ALNY) to discover, develop and commercialize new RNA interference (RNAi) therapeutics, which included an upfront $400 million, skewed the company’s earnings figures.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK